Stock Groups

U.S. FDA advisers weigh case for COVID-19 vaccine booster shots By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO : A health worker holds a vial containing Moderna COVID-19 Vaccine, at a Pop-Up Vaccination Site operated by SOMOS Community care during the COVID-19 pandemic that hit Manhattan, New York City. This was on January 29, 2021.

(Reuters) – Booster Doses of The Pfizer Inc (NYSE BioNTechSE COVID-19 vaccine increased severe disease protection among people over 40 years of age, Israel’s Health Ministry said to an independent panel of U.S Food and Drug Administration representatives on Thursday.

Meeting of U.S. FDA to discuss the necessity for booster shots Moderna (NASDAQ:) Inc. vaccine.

Israel, which closely monitors vaccines in its populace, stated in a slide presentation, that the administration of a booster dose resulted in greater protection against confirmed infections among those 16-plus.

 

 

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]